Richard Morse Joins Better Therapeutics and Will Lead Clinical Operations
Biotech expert will lead clinical operations and advance digital therapeutic candidates through FDA-clearance.
Richard brings nearly 20 years of biotech and pharma expertise across multiple therapeutic indications and in all phases of the clinical development lifecycle. In this newly created role, Richard will advance the development of new prescription digital therapeutics for treating cardiovascular and metabolic diseases.
“I’m very excited to be part of this pioneering effort and look forward to leading Better’s clinical research programs to validate the safety and efficacy of new digital therapies, and support the company’s regulatory objectives.”
Most recently, Richard served as Head of Clinical Operations at Adamas Pharmaceuticals. Previously, he held senior leadership roles with BioMarin, Pfizer Neuroscience and Biogen. During his career, his passion for innovation and focus on pragmatic data-driven decision making has led to the successful execution of clinical development programs across an impressive range of indications.
Richard earned his undergraduate degree in neuroscience from the University of Illinois at Urbana-Champaign, and graduate degrees from Case Western Reserve School of Medicine and the Harvard School of Public Health.